Palo Alto Weekly22h
Ex-Stanford employee found guilty of unlawful access, alteration of breast cancer database
A former employee of Stanford University was found guilty of accessing a clinical research database for a multisite breast ...
Former Stanford employee guilty of illegally accessing, altering breast cancer database
A former employee of Stanford University was found guilty of accessing a clinical research database for a multisite breast ...
Ex-Stanford research coordinator convicted of tampering with cancer study database
A jury found Naheed Mangi replaced patient medical data with erroneous information, insults about former boss.
Crime and Public Safety
A jury found Naheed Mangi replaced patient medical data with erroneous information, insults about former boss.
Blood Tests And Breastmilk: Why Investors Are Betting Big On Female Biology
As we enter 2025, the confluence of scientific advancement, market opportunity and industry validation suggests women's ...
If this biotech CEO succeeds millions of cancer patients could benefit
If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...
FiercePharma6d
Genentech, Novartis join forces to raise awareness of food allergies’ impact on families
Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...
Food Allergy Research & Education7d
FARE Teams Up with Genentech and Novartis to Launch Food Allergy Educational Initiative
To learn more about food allergies or access FARE resources, please visit foodallergy.org.
FierceBiotech13d
Genentech archives diversity reports amid site update, examines ‘potential implications of executive orders’
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s potential.
The Business Journals21d
With FDA approval, Genentech turns eye implant's focus to diabetes
The Susvimo implant — the size of a grain of rice — can be refilled by needle every six months. Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled ...
Business Wire22d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...